Markets:

Overview

News

Currencies

International

Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

17.80 +0.34 (+1.98%)

Streaming Delayed Price Updated: 1:22 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 09, 2025

From PureTech Health plc

Via Business Wire

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 08, 2025

Via Benzinga

PureTech Health plc Statement Regarding Press Speculation

April 07, 2025

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

March 11, 2025

From PureTech Health plc

Via Business Wire

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2025

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

February 12, 2025

From PureTech Health plc

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

January 27, 2025

From PureTech Health plc

Via Business Wire

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

January 09, 2025

From PureTech Health plc

Via Business Wire

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From PureTech Health plc

Via Business Wire

PureTech Appoints UBS as UK Corporate Broker

January 06, 2025

From PureTech Health plc

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 16, 2024

Via Benzinga

PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients ↗

December 16, 2024

PureTech Health's Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function improvement and dose-dependent benefits.

Via Benzinga

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗

December 16, 2024

Via Benzinga

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

December 16, 2024

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

December 11, 2024

From PureTech Health plc

Via Business Wire

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

December 09, 2024

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

November 20, 2024

From PureTech Health plc

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

November 05, 2024

From PureTech Health plc

Via Business Wire

PureTech to Present at Two Upcoming Investor Conferences

October 30, 2024

From PureTech Health

Via Business Wire

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

October 21, 2024

From PureTech Health plc

Via Business Wire

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

October 09, 2024

From PureTech Health plc

Via Business Wire

PureTech to Present at CHEST 2024 Annual Meeting

October 01, 2024

From PureTech Health

Via Business Wire

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades ↗

September 27, 2024

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without...

Via Benzinga

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

September 27, 2024

From PureTech Health plc

Via Business Wire

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 10, 2024

Via Benzinga

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

September 06, 2024

From PureTech Health plc

Via Business Wire

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 03, 2024

Via Benzinga

PureTech Health plc – Half-Year Report

August 28, 2024

From PureTech Health plc

Via Business Wire

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.